(3RB) Reckitt Benckiser - Ratings and Ratios

Reckitt Benckiser Group plc is a global leader in health, hygiene, and nutrition products, with a diverse portfolio that addresses everyday consumer needs. The company, founded in 1819 and headquartered in Slough, UK, has established itself as a trusted name across multiple categories. Its product range spans acne treatments under Clearasil, germ protection with Dettol, and personal care items like Durex condoms, catering to various aspects of personal health and wellness.

In the health sector, Reckitt Benckiser offers solutions for common ailments, including heartburn remedies like Gaviscon, pain relief through Nurofen, and respiratory care with Mucinex. The company also provides nutrition for infants and young children through brands like Enfamil, highlighting its commitment to early life nutrition and development.

The home and hygiene division includes brands such as Lysol for disinfectants and Finish for dishwashing products, ensuring a clean and safe environment for consumers. Additionally, Reckitt Benckiser addresses pest control and fabric care with Mortein and Vanish, respectively, showcasing a comprehensive approach to household needs.

Financially, Reckitt Benckiser presents a robust profile with a market cap of 40,827.94M EUR, indicating significant market presence. The trailing P/E ratio of 22.63 and forward P/E of 14.99 suggest a valuation that balances current performance with future growth potential. The price-to-book ratio of 4.24 reflects strong equity, while the price-to-sales ratio of 2.85 indicates efficient revenue generation.

For investors and fund managers, Reckitt Benckiser offers stability through its diversified product portfolio and established market positions, supported by a long-standing history and a broad global reach. This makes it a consideration for those seeking exposure to the consumer goods sector with a focus on health and hygiene.

Further details about the company can be found at https://www.reckitt.com.